Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118273 · ClinicalTrials.gov registry record · Phase 4
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
NCT01118273 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 162 participants.
The verdict
NCT01118273, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
Study Summary
The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination
Interventions
- DRUG Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg
- DRUG Naproxen Sodium 440 mg (BAYH6689)
- DRUG Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
- DRUG Naproxen Sodium 220 mg (BAYH6689)
- DRUG DPH 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118273
The ClinicalTrials.gov registry entry for NCT01118273 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg is the first listed.
NCT01118273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01118273 about?
NCT01118273 is a clinical study titled "Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine". The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination
What is the current status of trial NCT01118273?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2008-01. Estimated completion is 2008-02.
What interventions are being tested in trial NCT01118273?
The interventions under investigation include: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg (DRUG), Naproxen Sodium 440 mg (BAYH6689) (DRUG), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg (DRUG), Naproxen Sodium 220 mg (BAYH6689) (DRUG), DPH 50mg (DRUG).
Who is sponsoring clinical trial NCT01118273?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.